title: Cost consequences of the 340B drug discount program.
authors.affiliation: Section of Hematology/Oncology, Department of Pediatrics, University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA. rconti@uchicago.edu
authors.forename: Rena M
authors.initials: RM
authors.lastname: Conti
authors.forename: Peter B
authors.initials: PB
authors.lastname: Bach
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics; D002173:Cancer Care Facilities / Q000191:economics; D003132:Commerce; D017046:Cost Savings; D017047:Cost Sharing; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D006078:Government Programs; D006764:Hospitals, Community / Q000191:economics; D007348:Insurance, Health; D008484:Medicaid; D058991:Patient Protection and Affordable Care Act; D010818:Practice Patterns, Physicians'; D014481:United States
chemical_list: D000970:Antineoplastic Agents